Jupiter Therapeutics is a platform biotechnology company focused on creating a new class of cell-membrane based therapeutics. Jupiter uses cell engineering to make customized vesicles for immuno-oncology, gene therapy, and targeted drug delivery. Their first application in immuno-oncology is a highly feasible and differentiated approach that addresses major issues with CAR T-cells and bispecific antibodies. 
Xomics is a pre-IND stage biopharma that strives to translate our rapidly expanding knowledge of transporter proteins into novel, first-in-class medicines to address unmet medical needs in treating cancer, metabolic disorders and genetic diseases. Xomics has operations in San Francisco Bay Area and Shanghai.
Astellas Golden Ticket 2020 Golden Ticket Competition

Astellas is offering up to two Golden Tickets for pioneering scientific research that complements Astellas' innovation initiatives. For 2020, AVM is interested in all areas of discovery and new innovations for unmet medical needs, in particular the ones that have potential synergy with Astellas' Focus Area Approach. Read full article.

Astellas Golden Ticket winners will gain access to:
  • One year's priority admission or renewal to MBC BioLabs state-of-the-art lab and Fast-Track Core facility
  • Astellas' R&D scientists, business leaders and global network partners
Submit your non-confidential company presentation to by Friday, October 27, 2020, for your chance to be considered.
MBC BioLabs partners with Agilent

MBC BioLabs is delighted to welcome Agilent as its newest partner. Agilent is placing the following instruments at MBC BioLabs San Carlos 930 Brittan Fast-Track Core: Agilent 4150 TapeStation, Agilent AriaMx Real-Time PCRAgilent Seahorse XF HS Mini AnalyzerAgilent BioTek Cytation5 Automated Imaging and Plate Reader and Agilent BioTek 405TS Plate Washer

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
Siolta Therapeutics, a clinical-stage biotech company and MBC BioLabs San Carlos resident company, has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. Read full press release.
MBC BioLabs Congratulates Jennifer Doudna and Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
MBC BioLabs congratulates Jennifer Doudna and Emmanuelle Charpentier on being awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR-Cas9 system, a genome editing breakthrough that has revolutionized biomedicine. Doudna, also co-founder of Mammoth Biosciences, a MBC BioLabs alumni company, and Charpentier are the first women to win a Nobel Prize in the sciences together. Read full press release.